Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$7.56 USD
+0.07 (0.94%)
Updated Oct 1, 2024 03:59 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Vir Biotechnology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -615.12 | 515.84 | 528.58 | -298.67 | -174.68 |
Depreciation/Amortization & Depletion | 10.75 | -2.16 | 5.57 | 7.82 | 4.34 |
Net Change from Assets/Liabilities | -304.59 | 665.37 | -628.39 | 29.52 | 8.20 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 130.18 | 484.21 | 46.65 | 70.38 | 32.51 |
Net Cash From Operating Activities | -778.79 | 1,663.25 | -47.59 | -190.94 | -129.63 |
Property & Equipment | -21.57 | -68.01 | -21.82 | -6.37 | -8.94 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 186.20 | -1,125.46 | -119.00 | -3.49 | -247.22 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 164.63 | -1,193.46 | -140.81 | -9.86 | -256.16 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 7.77 | 36.22 | 100.59 | 533.97 | 444.88 |
Issuance (Repayment) of Debt | -0.29 | -0.26 | -0.26 | -0.25 | 4.37 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -1.20 | 0.00 | -4.25 | 0.00 |
Net Cash from Financing Activities | 7.48 | 34.76 | 100.33 | 529.47 | 449.24 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -606.68 | 504.55 | -88.07 | 328.67 | 63.45 |
Cash at Beginning of Period | 867.97 | 363.42 | 451.49 | 122.82 | 59.36 |
Cash at End of Period | 261.29 | 867.97 | 363.42 | 451.49 | 122.82 |
Diluted Net EPS | -4.59 | 3.83 | 3.96 | -2.51 | -5.76 |
Fiscal Year End for Vir Biotechnology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -203.65 | -65.28 | -615.12 | -499.14 | -335.73 |
Depreciation/Amortization & Depletion | 11.65 | 4.76 | 10.75 | 4.92 | -1.98 |
Net Change from Assets/Liabilities | -84.50 | -82.15 | -304.59 | -271.84 | -242.15 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 89.26 | 33.28 | 130.18 | 95.21 | 64.83 |
Net Cash From Operating Activities | -187.24 | -109.39 | -778.79 | -670.86 | -515.03 |
Property & Equipment | -1.63 | -1.34 | -21.57 | -20.04 | -16.32 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 241.65 | 29.76 | 186.20 | 289.48 | 344.72 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 240.03 | 28.42 | 164.63 | 269.44 | 328.39 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 3.23 | 0.22 | 7.77 | 6.00 | 5.66 |
Issuance (Repayment) of Debt | -0.14 | -0.07 | -0.29 | -0.20 | -0.13 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 3.09 | 0.15 | 7.48 | 5.80 | 5.52 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 55.88 | -80.82 | -606.68 | -395.62 | -181.11 |
Cash at Beginning of Period | 261.29 | 261.29 | 867.97 | 867.97 | 867.97 |
Cash at End of Period | 317.18 | 180.47 | 261.29 | 472.35 | 686.86 |
Diluted Net EPS | -1.02 | -0.48 | -0.86 | -1.22 | -1.45 |